The impact and correlation of lymphadenectomy with outcomes in patients with uterine sarcoma: A systematic review
1 Obstetrics and Gynecology Consultant, Head of gyne oncology Department, First Health Cluster, King Saud Medical City, Maternal Hospital, Riyadh, Saudi Arabia.
2 Obstetrics and Gynecology Associate Consultant, Obstetrics and Gynecology Department, First Health Cluster, King Saud Medical City, Maternal Hospital, Riyadh, Saudi Arabia.
3 Obstetrics and Gynecology Resident, Dr. Sulaiman Al-Habib Medical Group, Riyadh, Saudi Arabia.
4 Obstetrics and Gynecology Resident, Second Health Cluster, Alyamama Hospital,Riyadh, Saudi Arabia.
5 Gynecological oncology chief fellow, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
6 Obstetrics and Gynecology Resident, Maternity and Children Hospital, Aljouf, Saudi Arabia.
Review Article
World Journal of Advanced Research and Reviews, 2024, 24(01), 169–175
Publication history:
Received on 21 August 2024; revised on 28 September 2024; accepted on 30 September 2024
Abstract:
Background: Sarcomas are an uncommon type of smooth muscle tumors in the uterus. The most popular form of treatment for uterine sarcomas is surgery. There is disagreement, nonetheless, over the best course of action for initial surgery. The aim of this systematic review was to examine the potential association between patient outcomes and the effects of LAD in individuals diagnosed with uterine sarcoma.
Method: We conducted a comprehensive search of the PubMed database to identify publications assessing the impact of LAD on patients with uterine sarcoma that were published between 2009 and 2024. Based on the references in the studies that we included, we also conducted a search of the PubMed database. To find more relevant studies, the bibliographies of each pertinent paper were thoroughly reviewed. This review only includes studies that were published in English.
Results: We included 7 papers in this systematic review, totaling 7896 patients. Four publications examined ESS, four studies examined LMS, two articles examined adenosarcoma, one study examined carcinosarcoma, and one study examined rhabdomyosarcoma. For individuals with low-grade ESS or adenosarcoma, LAD was not linked to a better prognosis. The survival rate was lower for patients with leiomyosarcoma who had LAD. Those who had LAD and had high-grade undifferentiated ESS fared better. LAD did not significantly correlate with RFS or OS in uterine sarcoma patients.
Conclusion: Resection of lymph nodes or LAD has minimal potential benefit in terms of prognosis and clinical value.
Keywords:
Lymphadenectomy; Uterine sarcoma; Outcome; Survival
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0